CTAC recognized for its contribution to the Common Drug Review (CDR)
june 8, 2015
CTAC was recently recognized by the Canadian Agency for Drugs and Technology in Health (CADTH) for its support of the Common Drug Review (CDR). We are one of 17 groups to have submitted more than 5 patient input reports during the first five years since their Call for Patient Input was announced in 2010.
The Common Drug Review plays an instrumental role in informing the decision-making process that determines which drugs will be eligible for public reimbursement.
At CTAC we believe that everyone should have equitable access to life saving drugs and it is for that reason that we monitor HIV and hepatitis C drugs in development in the pipeline and host patient input consultations on those drugs once they are approved for use in Canada. The patient input information on HIV and HCV drugs we provide the Common Drug Review helps inform the CADTH recommendations to provincial and territorial public drugs plans.
We are pleased to have been recognized by CADTH for our efforts and we will continue to support vital HIV and HCV drugs through our Patient Input Consultations and the Common Drug Review.